[Antifungal therapy in special situations: resistant candidiasis and aspergillosis].
Fungal infections are an increasingly frequent problem in oncohematological patients with febrile neutropenia and hematopoietic precursors transplant recipients. According to the definitions of the EORTC/MSG Consensus Group, the term invasive fungal infection (IFI) is preferred nowadays to name this group of infections. This aims at highlighting the complex disease resulting from a fungal infection involving higher morbidity, longer hospital stays, increased health care costs and higher mortality risk. Candidiasis and aspergillosis account for about 80% of IFIs in oncohematological patients, while Fusarium diseases, mucormycosis, among others, are emerging infections.
Rabagliati
R
R
Departamento de Medicina Interna, Pontificia Universidad Catolica de Chile, Santiago, Chile.
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D025141:Drug Resistance, Fungal; D006801:Humans
D000935:Antifungal Agents